Revance Therapeutics - About the company
Revance Therapeutics is an acquired company based in Newark (United States), founded in 2002 by . It operates as a Developer of neurotoxin aesthetic and therapeutic products for skin treatments. Revance Therapeutics has raised $155M in funding from investors like EW Healthcare Partners, Delphi Ventures and Medicis Pharmaceutical. The company has 177 active competitors, including 49 funded and 58 that have exited. Its top competitors include companies like Hugel, Dermavant and SkinMedica.
Company Details
Developer of neurotoxin aesthetic and therapeutic products for skin treatments. It focused on developing innovative products in the aesthetic medicine and personal wellness categories. It has developed a platform technology that enables the delivery of large macromolecules and other potent molecules across the skin. Its aesthetics pipeline includes RT001 for lateral canthal lines and RT002 for glabellar lines. It has the same products as therapies for Hyperhidrosis and Cervical Dystonia.
- Website
- Social
- Phone Number
- +1
Key Metrics
Founded Year
2002
Location
Newark, United States
Stage
Acquired
Total Funding
in 5 rounds
Latest Funding Round
Investors
Ranked
1st among 177 active competitors
Annual Revenue
as on Dec 31, 2022
Employee Count
as on Dec 31, 2023
Similar Companies
Hugel &
Exit Details
Acquired by Crown Laboratories (Feb 08, 2025)
Legal entities associated with Revance Therapeutics
Revance Therapeutics is associated with 3 legal entities given below:
Legal Entity Name | Date of incorporation | Revenue | Net Profit | Employee Count |
|---|---|---|---|---|
Apr 25, 2022 | - | 174 | 573 | |
Dec 31, 2001 | - | 963 | 437 | |
Dec 22, 2009 | $133M (as on Dec 31, 2022) | 849 | 580 |
Get your free copy of Revance Therapeutics's company profile
Revance Therapeutics's acquisition details
Revance Therapeutics got acquired by Crown Laboratories on Feb 08, 2025.
Click to take a look at Revance Therapeutics's acquisition in detail
Revance Therapeutics's funding and investors
Revance Therapeutics has raised a total funding of $155M over 5 rounds. Its first funding round was on Dec 12, 2007.
Revance Therapeutics has 18 institutional investors including EW Healthcare Partners, Delphi Ventures and Medicis Pharmaceutical.
Here is the list of recent funding rounds of Revance Therapeutics:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Oct 22, 2013 | $10M | Series E | 1874511 | 7226789 | - |
Feb 22, 2013 | $33M | Series E | 4379916 | 8577414 | |
Jan 08, 2013 | $63.4M | Series D | 8242197 | 6604697 | , Technology Partners, and |
Access funding benchmarks and valuations. Sign up today!View details of Revance Therapeutics's funding rounds and investors
Revance Therapeutics's founders and board of directors
The founders of Revance Therapeutics is . is the CEO of Revance Therapeutics.
View details of Revance Therapeutics's Founder profiles and Board Members
Revance Therapeutics's employee count trend
Revance Therapeutics has 597 employees as of Dec 23. The total employee count is 11.8% more than what it was in Dec 22. Here is Revance Therapeutics's employee count trend over the years:
Uncover Revance Therapeutics's growth story! Sign up today!Revance Therapeutics's Competitors and alternates
Top competitors of Revance Therapeutics include Hugel, Dermavant and SkinMedica. Here is the list of Top 10 competitors of Revance Therapeutics, ranked by ÃØÃÜÑо¿Ëù score :
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | ÃØÃÜÑо¿Ëù Score |
|---|---|---|---|---|---|
1st | Revance Therapeutics 2002, Newark (United States), Acquired | Developer of neurotoxin aesthetic and therapeutic products for skin treatments | $155M | Hercules Capital, Athyrium Capital ManagementÌý&²¹³¾±è;Ìý | 72/100 |
2nd |  Hugel 2001, Chuncheon-si (South Korea), Acquired | Developer of therapeutics in the field of aesthetics | - | Mubadala, IMM InvestmentÌý&²¹³¾±è;Ìý | 65/100 |
3rd | Dermavant 2016, Phoenix (United States), Acquired | Developer of small molecule based therapeutics for the treatment of inflammatory skin diseases | $160M | 64/100 | |
4th | SkinMedica 1999, Carlsbad (United States), Acquired | Developer and manufacturer of skin care products | $94.2M | Apax, Aisling CapitalÌý&²¹³¾±è;Ìý | 63/100 |
5th | Sol-Gel Technologies 1998, Ness Ziona (Israel), Public | Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis. | $26M | Challenge Fund - Etgar, JVPÌý&²¹³¾±è;Ìý | 63/100 |
6th |  Bausch Health 1960, Laval (Canada), Public | Developer of therapeutics for the treatment of multiple diseases | - | Aisling Capital, ValueAct CapitalÌý&²¹³¾±è;Ìý | 61/100 |
7th |  Biosplice Therapeutics 2008, San Diego (United States), Series D | Provider of splicing modulation development solutions for multiple diseases | $778M | Sands Capital Ventures, Starling GroupÌý&²¹³¾±è;Ìý | 59/100 |
8th |  Castle Creek Pharma 2015, Basking Ridge (United States), Series C | Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders | $663M | 59/100 | |
9th | Develops plant-derived collagen products for tissue repair, 3D bio-printing | $16.3M | 59/100 | ||
10th | Biofrontera 1997, Leverkusen (Germany), Public | Provider of solutions for therapeutic and consumer products in dermatology | - | Deutsche Balaton, Ìý&²¹³¾±è;Ìý | 58/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Revance Therapeutics's competitors? Click to see the top ones
Revance Therapeutics's Investments and acquisitions
Revance Therapeutics has made no investments or acquisitions yet.
Reports related to Revance Therapeutics
Here is the latest report on Revance Therapeutics's sector:
View
News related to Revance Therapeutics
Media has covered Revance Therapeutics for a total of 82 events in the last 1 year, 6 of them have been about company updates and 2 about people movement.
•
•
PR Newswire•Apr 09, 2025•Revance Therapeutics
•
PR Newswire•Apr 09, 2025•Revance Therapeutics
•
GlobeNewswire•Mar 07, 2025•Revance Therapeutics,
•
PR Newswire•Mar 02, 2025•Revance Therapeutics,
•
Benzinga•Mar 01, 2025•Revance Therapeutics,
•
Benzinga•Feb 26, 2025•Revance Therapeutics,
•
•
•
PR Newswire•Feb 20, 2025•Revance Therapeutics, , ,
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Frequently asked questions about Revance Therapeutics
When was Revance Therapeutics founded?
Revance Therapeutics was founded in 2002.Where is Revance Therapeutics located?
Revance Therapeutics is located in Newark, United States.Is Revance Therapeutics an acquired company?
Revance Therapeutics got acquired by Crown Laboratories on Feb 08, 2025.When was the latest funding round of Revance Therapeutics?
Revance Therapeutics's latest funding round was on Oct 22, 2013.What is the annual revenue of Revance Therapeutics?
Annual revenue of Revance Therapeutics is $133M as on Dec 31, 2022.Our Lite Plan Awaits you - Its Free!
Sign up now to unlock full access to curated data
4M+ Companies- 212K+ Investors
- 580K+ Funding Rounds
- 207K+ Acquisitions
- 2.9K+ Sectors
- 57K+ Business Models
Are you a Founder ?
Explore our recently published companies
- Al Mutawa Certified - Kuwait based, 1951 founded, Unfunded company
- ChatGenius - Dhaka based, 2011 founded, Unfunded company
- Zantus Lifesciences - Mumbai based, 2024 founded, Unfunded company
- Ecco Electronics - Delhi based, 2014 founded, Unfunded company
- Basta - Reykjavik based, 2022 founded, Unfunded company
- Ligwood - Madison based, 2024 founded, Funding Raised company
